Company · HUM
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
Humana’s Q1 2026 operating cash flow surged 278% to $1.25B, confirming the Medicare Advantage actuarial crisis is stabilizing — while 22% membership growth and a CenterWell platform valued at zero in consensus models point to a trough-earnings setup with $25+ EPS by 2028.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| HUM Humana | LONG | — | — | — | — | |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
| PFE Pfizer | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
